210 related articles for article (PubMed ID: 16936779)
1. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Prabhu S; Saadat D; Zhang M; Halbur L; Fruehauf JP; Ong ST
Oncogene; 2007 Feb; 26(8):1188-200. PubMed ID: 16936779
[TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
Zhang M; Fu W; Prabhu S; Moore JC; Ko J; Kim JW; Druker BJ; Trapp V; Fruehauf J; Gram H; Fan HY; Ong ST
Mol Cell Biol; 2008 Oct; 28(20):6496-509. PubMed ID: 18694961
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.
Connor JH; Lyles DS
J Virol; 2002 Oct; 76(20):10177-87. PubMed ID: 12239292
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
[TBL] [Abstract][Full Text] [Related]
8. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
10. Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes.
Huang BP; Wang Y; Wang X; Wang Z; Proud CG
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H505-14. PubMed ID: 19074679
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
12. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
[TBL] [Abstract][Full Text] [Related]
14. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
15. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
[TBL] [Abstract][Full Text] [Related]
16. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
Carayol N; Vakana E; Sassano A; Kaur S; Goussetis DJ; Glaser H; Druker BJ; Donato NJ; Altman JK; Barr S; Platanias LC
Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12469-74. PubMed ID: 20616057
[TBL] [Abstract][Full Text] [Related]
17. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
18. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
19. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
